DNAPrint Genomics Documente
Documente
0
Ticker
DNAG
ISIN
US23324Q2021
DNAPrint Genomics SEC Filings
Tip | Raport | Dată |
|---|---|---|
| Nu sunt disponibile documente | ||
DNAPrint Genomics Documente 2026
Această pagină conține toate documentele oficiale și depunerile SEC pentru acțiunea DNAPrint Genomics (DNAG, ISIN: US23324Q2021). Aceasta include rapoarte anuale (Form 10-K), rapoarte trimestriale (Form 10-Q) și tranzacții interne (Form 4). În prezent sunt disponibile 0 documente. Datele sunt actualizate regulat pentru a oferi investitorilor o prezentare generală completă a depunerilor de reglementare ale DNAPrint Genomics.
DNAPrint Genomics Analiza acțiunilor
DNAPrint Genomics DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable.